Valuation: Insmed Incorporated

Market Cap 27.59B 23.91B 22.42B 20.44B 38.46B 2,633B 39.08B 264B 103B 1,318B 104B 101B 4,397B P/E 2026 *
-79.9x
P/E 2027 * 113x
Enterprise Value 26.96B 23.37B 21.9B 19.97B 37.58B 2,573B 38.18B 258B 101B 1,288B 101B 99.01B 4,296B EV / Sales 2026 *
14.9x
EV / Sales 2027 * 9.22x
Free-Float
99.49%
Yield 2026 *
-
Yield 2027 * -
1 day-4.50%
1 week-4.69%
Current month+28.12%
1 month+15.75%
3 months+7.07%
6 months-15.07%
Current year-27.41%
1 week 126.13
Extreme 126.13
135.5
1 month 96.42
Extreme 96.42
137.7
Current year 90.39
Extreme 90.39
186.19
1 year 90.39
Extreme 90.39
212.75
3 years 21.21
Extreme 21.21
212.75
5 years 16.04
Extreme 16.04
212.75
10 years 10.21
Extreme 10.21
212.75
Manager TitleAgeSince
Chief Executive Officer 57 2012-09-09
Director of Finance/CFO 45 2020-01-30
Chief Tech/Sci/R&D Officer 62 2019-12-18
Director TitleAgeSince
Chairman 75 2009-06-15
Chairman 57 2018-11-07
Director/Board Member 72 2014-05-28
Date Insider Type Main position Quantity % Market Cap.
8/6/26 Fiscal year

Chief Technology Officer

81,519 0.0376%
7/23/26 Fiscal year

Chief Executive Officer

32,100 0.0148%
7/9/26 Fiscal year

Chief Executive Officer

32,097 0.0148%
Change 5-day change 1-year change 3-year change Capi.($)
-4.50%-4.69%+2.82%+463.22% 28.89B
+2.07%+13.76%+65.44%+106.53% 70.1B
-0.87%+0.08%+36.96%+65.91% 54.93B
-0.39%-0.31%+48.35%+7.45% 23.9B
-0.67%+1.02%-18.32%-13.84% 23.3B
+0.35%+12.02%+257.19%+466.50% 18.41B
-0.59%+7.88%+40.87%-20.56% 18.77B
-1.33%+3.44%+25.60%+580.70% 16.1B
+0.46%-3.05%+31.49%+135.18% 12.48B
-1.90%-0.28%+328.16%+196.67% 12.32B
Average -0.62%+4.21%+81.86%+198.78% 27.92B
Weighted average by Cap. -0.29%+3.79%+63.68%+164.70%

Financials

2026 *2027 *
Net sales 1.81B 1.57B 1.47B 1.34B 2.52B 172B 2.56B 17.28B 6.75B 86.3B 6.78B 6.63B 288B 2.87B 2.49B 2.33B 2.12B 4B 274B 4.06B 27.43B 10.71B 137B 10.76B 10.53B 457B
Net income -326M -283M -265M -242M -455M -31.12B -462M -3.12B -1.22B -15.58B -1.22B -1.2B -51.97B 229M 198M 186M 170M 319M 21.84B 324M 2.19B 855M 10.93B 859M 841M 36.47B
Net Debt -632M -548M -513M -468M -881M -60.3B -895M -6.04B -2.36B -30.18B -2.37B -2.32B -101B -1.16B -1B -940M -857M -1.61B -110B -1.64B -11.07B -4.32B -55.26B -4.34B -4.25B -184B
Logo Insmed Incorporated
Insmed Incorporated specializes in the research and development of drugs for the treatment of respiratory, immunological, inflammatory, neurological, and rare diseases. At the end of 2025, the group has two products in the commercialization phase: ARIKAYCE® for the treatment of lung infection caused by the Mycobacterium avium complex and BRINSUPRI® for the treatment of bronchiectasis (dilation of the bronchi) unrelated to cystic fibrosis. The United States account for 74.7% of net sales.
Employees
1,664
Date Price Change Volume
26-08-13 US$126.33 -4.50% 2,479,533
26-08-12 US$132.28 -0.22% 1,563,224
26-08-11 US$132.57 -1.62% 2,728,711
26-08-10 US$134.75 +2.78% 3,630,056
26-08-07 US$131.10 -1.09% 4,904,624
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
126.33USD
Average target price
200.05USD
Spread / Average Target
+58.35%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. INSM Stock